PharmaShots | Incisive News in 3 Shots

Subscribe Now

Celltrion

Celltrion Launches Yuflyma (biosimilar, adalimumab) for the Treatment of Multiple Chronic Inflammatory Disease in Canada

Celltrion Launches Yuflyma (biosimilar, adalimumab) for the Treatment of Multiple Chronic Inflammatory Disease in Canada

April 11, 2022

Celltrion Reports Results of CT-P39 (biosimilar, omalizumab) in P-I Study for Asthma and Chronic Idiopathic Urticaria

Celltrion Reports Results of CT-P39 (biosimilar, omalizumab) in P-I Study for Asthma and Chronic Idiopathic Urticaria

March 15, 2022

Celltrion’s Yuflyma (biosimilar, adalimumab) Receives Health Canada's Approval for the Treatment of Chronic Inflammatory Diseases

Celltrion’s Yuflyma (biosimilar, adalimumab) Receives Health Canada's Approval for the Treatment of Chronic Inflammatory Diseases

February 1, 2022

Celltrion Reports Results of Herzuma (biosimilar, rastuzumab) + Gedatolisib in P-II Study for the Treatment of Metastatic Breast Cancer

Celltrion Reports Results of Herzuma (biosimilar, rastuzumab) + Gedatolisib in P-II Study for the Treatment of Metastatic Breast C...

December 14, 2021

PharmaShots Weekly Snapshots (November 15 - 19, 2021)

PharmaShots Weekly Snapshots (November 15 - 19, 2021)

November 19, 2021

AstraZeneca and Moderna Present Results of AZD8601 in P-IIa EPICCURE Trial for the Treatment of Heart Failure at AHA 2021

AstraZeneca and Moderna Present Results of AZD8601 in P-IIa EPICCURE Trial for the Treatment of Heart Failure at AHA 2021

November 16, 2021

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us